In esophageal cancer, aside from the first-line radiotherapy and chemotherapy combined with anti-PD-L1 treatment, which has proven effective in many phase III trials, trials combining neoadjuvant immunotherapy with chemotherapy are also gradually underway. Here, CD274 is linked to esophageal cancer.